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Summary We have assessed the tumour markers placental alkaline phosphatase (PLAP), lactate dehy-
drogenase (LD), and human chorionic gonadotrophin (p HCG) using 2,000 serum samples from 286 patients
with seminoma. The ROC curves show that no one marker performs adequately for the detection of disease
either at initial staging or during follow-up. We used a Markov model heuristically to devise strategies, in
which marker results were assessed in combination, which might be useful in clinical practice. We found that
the best strategy was to consider a test result abnormal only if either the P HCG was >6 UL1' or the LD was
>400 U 1-l and the PLAP level was >60 U 1- . This will detect about 50% of patients with disease and the
false-positive rate is 2%. In practical terms this means that PLAP need only be estimated in patients whose
HCG is <6 IU 1I and whose LD is >400 U 1-'.
The availability of the specific tumour markers alpha-foeto-
protein and the P subunit of human chorionic gonadotrophin
(13 HCG) greatly facilitates the management of patients with
non-seminomatous germ cell tumours (Bosl et al., 1983). It is
unfortunate that no similarly useful tumour markers have
been identified for seminomas. About 30% of seminomas
produce PHCG (Fossa & Fossa, 1989; Dieckmann et al.,
1989). Increased levels of lactate dehydrogenase (LD) may be
found in patients with seminoma but this enzyme cannot be
considered specific (Taylor et al., 1986; von Eyben et al.,
1988; Fossa & Fossa, 1989). A heat-stable alkaline phos-
phatase isoenzyme, placental alkaline phosphatase (PLAP),
has been suggested as a potential marker for seminoma
(Epenetos et al., 1985; De Broe & Pollet, 1988) but we have
recently shown that, considered alone, its clinical usefulness
is limited (Nielsen et al., 1990). PLAP is elevated in healthy
smokers and this further complicates its use as a marker for
seminoma.
An obvious solution to the problem is to consider P HCG,
LD and PLAP together in patients with seminoma in the
hope that their deficiencies, when considered individually,
might disappear when considered jointly. It has recently been
suggested (Fossa & Fossa, 1989) that, by considering both
LD and P HCG together, 70% of relapses in patients with
seminoma might be identified.
We have investigated the use of combinations of PLAP,
HCG and LD in the assessment of patients with seminoma
using data from 286 patients treated at Princess Margaret
Hospital (PMH). We have analysed these potential markers
not simply in terms of ability to detect relapse but have also
considered the positive predictive value of a given test result
as well as estimating the extent to which false positive results
might cause problems.
Patients and methods
The records of 286 consecutive patients with pure seminoma
referred to the testis clinic at PMH between January 1983
and December 1988 were reviewed. No patient whose tumour
at any time showed evidence of alpha-foetoprotein produc-
tion was included. The pathology of the primary tumour has
been reviewed at this hospital and only patients with pure
seminomas have been included in this analysis. Patients were
staged at presentation according to the Royal Marsden stag-
ing system (Duchesne et al., 1990). There were 229 patients
with Stage I, 30 patients with Stage IIA, 11 patients with
Stage IIB, 11 patients with Stage IIC and five patients with
Stage III disease.
A total of 2,000 serum samples were obtained from these
patients, although not all samples had been assayed for all
three markers under consideration. Lactate dehydrogenase
(LD) was measured using an NADH method on a standard
autoanalyser (SMAC). The beta subunit of human chorionic
gonadotrophin (pHCG) was measured using an enzyme-
linked immunological method (Hybritech). Placental-like alk-
aline phosphatase (PLAP) was measured by a kinetic enzyme
method (Anstiss et al., 1971). The presence or absence of
disease at the time of sampling was determined from a review
of the clinical course of the patient and was made without
reference to the results of serum markers. One thousand
seven hundred and seventeen samples were from patients
known to be disease-free, 219 samples were from patients
with active disease, disease status was classed as unknown for
64 samples. The patients' smoking habits were ascertained by
direct questioning.
The overall design of the study is summarised in Figure 1.
The patients were divided randomly, but unequally, into two
groups: a data generating set and a test set. The data
generating set, 1,406 samples from 201 patients was deliber-
ately larger than the test group, 596 samples from 85
patients. The data generating set was used to produce in-
formation on the performance of the various markers that
could be used to generate hypotheses that could then be
investigated using the test set. All data were entered into an
IBM-compatible microcomputer using dBase IV (Ashton-
Tate). The programmes used to handle the data were
specifically written for the study.
Receiver operating characteristic (ROC) curves were pro-
duced by selecting a series of thresholds for each marker and
using these to divide results dichotomously. As the thres-
holds, used to define the boundary between a normal and an
abnormal test result, rise then both the false positive rate and
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Figure 2 The Markov process used for assaying possible stra-
tegies.
Figure 1 A schematic version of the design of the study.
the true positive rate will tend to decrease. This relationship
can be displayed graphically if false positive rate (FPR) is
plotted against the true positive rate (TPR) for a variety of
threshold values. A useful test is one with a low FPR and a
high TPR the ROC curve will be steep initially and then,
once TPR is maximal at around 90 to 100%, flatten out. The
ROC curve for an uninformative test will be close to a line
drawn at 45 degrees through the origin.
Inspection of the ROC curves suggested marker thresholds,
or combinations of marker thresholds, that might prove
clinically useful in discriminating between patients with di-
sease and those free from disease. The most promising
strategies were then assessed using a Markov model. Such a
model can usefully simulate the follow-up of patients with
cancer (Beck & Pauker, 1983; Munro & Warde, 1991) and
has the advantage that it is sufficiently flexible and dynamic
to enable a variety of threshold values to be assessed rapidly.
A Markov process is a cyclical process in which, during
each cycle, the movement of patients between various states
is governed by probabilities that have been previously
defined. This part of the analysis used a standard decision
analysis programme (smltree). A schematic form of the Mar-
kov cycle used in this study is shown in Figure 2. The
end-points selected for the evaluation of each strategy were:
percentage of all relapses that were detected by the given
strategy; cumulative percentage of false positive test results
generated for each patient. The model assumed a follow up
period of 3 years with tests performed every 2 months for the
first 2 years and every 3 months for the third year. The
probability of relapse at each cycle varied according to the
interval after treatment since the cumulative-time-to-relapse
curve for seminoma indicates that the majority of relapses
occur within a year of initial management (Duchesne et al.,
1990; Duncan & Munro, 1987). The model was used to
simulate two different sets of clinical circumstances: patients
followed up after prophylactic retroperitoneal radiotherapy
for Stage I seminoma (where the total relapse rate was set at
5%) and patients followed on a surveillance policy for Stage
I seminomas (where the total relapse rate was set at 15%).
The former figure overestimates the relapse rate after radio-
therapy quite deliberately in order to define the maximum
possible benefit that could be expected from the use of
tumour markers in this context. The model was run for a
total of 36 cycles at a cycle length of one month: this
corresponds to 3 years of clinical follow up. Patients who
relapsed were removed from the cycle by entering the states,
defined as absorbing states, 'true positive' or 'false negative'.
Patients with false positive results re-entered the cycle via the
non-absorbing state, 'well'. The cumulative number of false
positive results was recorded for all 36 cycles as was the total
number of relapses and the total number of true positive
results. The proportion of relapses detected by the given
strategy was calculated by: total number of true positive
results/total number of relapses.
The Markov model was used as a sieve to eliminate
theoretically enticing, but practically misleading, strategies.
Those strategies which performed reasonably in the Markov
analysis were then applied to the basic data in the data
generating set. The false positive rate (FPR), true positive
rate (TPR), and likelihood ratio (LR) were calculated directly
from the data. Likelihood ratios were obtained by dividing
TPR by FPR. The test set was then analysed using the
chosen strategies and the results were compared to the
predictions made by the data generating set.
Since the performance of any diagnostic test depends upon
the prevalence of the condition that is being sought we tested
the strategies under various conditions. A prevalence, or
prior probability ofdisease, of 30% was assumed for patients
at initial staging after orchiectomy. For follow-up visits
prevalence rates of 1% and 5% were applied. The likelihood
ratio is a useful tool in defining the probability of a positive
test result actually indicating disease (post-test probability) in
a patient whose prior (or pre-test) probability of disease can
be estimated. The relevant equations are:
Pre-test odds = pretest probability/pretest probability-i .
Post test odds = LR x pretest odds.
Post test probability = post test odds/post test odds + 1.
Results
The basic statistical data for all 286 patients (2,000 samples)
are summarised in Table I. There were no systematic
differences between the results calculated using all available
samples and those calculated using only the initial sample
from each patient. The discrepancies between mean and
median values when the various groups are compared indi-
cates that the tumour marker levels are not normally dis-
tributed in these populations. The mean levels of PLAP, LD
and P HCG are significantly higher in patients with disease.
The level of PLAP is significantly elevated in smokers with-
out disease compared with non-smokers who are disease-free.
PLAP and LD were higher in patients in clinical stages IIC
and III (defined as high bulk) than in patients in stages IIA
and IIB (defined as low bulk). There was no such trend for
, HCG. The mean values, with 95% confidence limits in
brackets, are as follows:
Low bulk (IIA & IIB): P HCG 12.7 IU 11 (- 2.3 to 27.7)
LD 580U l' (21 to 1139)
PLAP 22.4U1-I (13.6 to 31.2)
High bulk (IIC & III): PHCG 4.29 IUI' (1.7 to 6.8)
LD 1969U1-' (680 to 3258)
PLAP 211.0U1-' (96.1 to 325.9)TIJMOUR MARKERS IN SEMINOMA 539
Table I Statistical summary of data
Table Ta
Group No. Mean 95% CL Median Range
All without disease-s 1627 2.62 2.57 to 2.67 2.50 1.00 to 29.00
P 199 2.76 2.54 to 2.98 2.50 1 to 20.00
All with disease-s 191 48.45 23.80 to 73.10 2.50 1.00 to 1420.00
P 54 28.07 5.89 to 50.25 2.50 1.00 to 480.00
Smokers without disease-s 423 2.56 2.49 to 2.63 2.50 2.00 to 15.00
P 40 2.70 2.33 to 3.07 2.50 2.00 to 10.00
Smokers with disease-s 58 120.12 43.76 to 196.48 2.50 1.00 to 1420.00
P 12 67.90 (-) 15.3 to 152.1 2.50 2.50 to 480.00
Table lb
Group No. Mean 95% CL Median Range
All without disease-s 858 153 148 to 157 137 30 to 672
P 122 211 189 to 234 146 97 to 672
All with disease-s 99 797 545 to 1050 194 69 to 8365
P 34 1018 424 to 1612 394 69 to 8365
Smokers without disease-s 220 150 141 to 160 134 71 to 596
P 26 210 166 to 253 142 106 to 453
Smokers with disease-s 31 1075 438 to 1712 180 99 to 8365
P 8 2222 165 to 4278 242 99 to 8365
Table Ic
Group No. Mean 95% CL Median Range
All without disease-s 1422 19 19 to 20 15 1 to 153
P 100 24 20 to 27 18 1 to 132
All with disease-s 118 74 56 to 93 25 1 to 569
P 24 100 39 to 161 32 7 to 569
Smokers without disease-s 384 29 26 to 31 22 3 to 140
P 25 34 27 to 41 27 11 to 79
Smokers with disease-s 34 75 31 to 120 22 1 to 569
P 3 383 137 to 629 501 78 to 569
-s, datacalculated using the serum sample as the unitofobservation (total =2,000). -p, data
calculated using only the initial sample from each patient (total = 286). Ia: data on P HCG in
IU1'; lb: data on LD in U-1; Ic: data on PLAP in U-1.
The ROC curves for P HCG, LD and PLAP obtained from
the data generating set are shown in Figure 3. The most
specific marker is P HCG but it is relatively insensitive, detec-
ting only about 30% of relapses. The curve for LD is some-
what similar, with a 30% TPR at a FPR of 5% when the
threshold is 400 U I-. The curve for PLAP shows inferior
discriminatory ability: even with FPR as high as 10% the
TPR is still only 30%. The high specificity of P HCG when
the threshold is >6 IU [' suggests that this should be the
cornerstone of any strategy since this gives a TPR that is
near the maximum that can be achieved and the FPR is only
0.5%. Traditionally, markers have been used in strategies
using 'or': if P HCG is abnormal or LD is abnormal then
suspect recurrence. The results of a Markov analysis of this
approach are shown in Figure 4. Although nearly 85% of
relapses could be detected using thresholds of 20 U l- for
PLAP, 300 U I` for LD, and 3 IU I` for 13 HCG, the false-
positive rate with such an approach is nearly 35%. This
suggested that a different set of strategies might be worth
exploring. The high specificity of P HCG could be retained
but its low sensitivity complemented by the more sensitive,
but less specific, markers LD and PLAP: if P HCG is abnor-
mal or both LD and PLAP are abnormal then suspect recur-
rence. A variety of such strategies were tested using the
Markov model and some of the results are summarised in
Table II. This shows performance of the strategies when
applied to the test set, 'observed' values, as well as to the
data generating set, 'predicted' values. Although the corres-
pondence ofTPR, FPR, and hence LR, is not exact. the rank
order, based upon LR, is the same for both groups. The
disparities in LR are to be expected given that it is a ratio
derived from two separately derived indices and any individ-
ual errors in the estimates will therefore be multiplied.
The best strategy is P HCG >6 IU 1' or LD >400 U I`
and PLAP >60 U 1'. This will detect about 50% of relapses
and the FPR is <2%. Although the strategy P HCG
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Figure 3 ROC curves from the data generating set a, P HCG
(IU1'). b, LD (U 1-). c, PLAP (U I-'). Labelled points indicate
threshold values.
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Figure 4 A summary of results from the Markov analysis using
an 'or' strategy. The P HCG threshold was >6 IU l-l through-
out. The PLAP and LD strategies were varied as shown. a,
proportion of relapses detected. b, percentage of false-positive
results.
Table H TheTPR, FPRand LR forseven strategies, predicted dataare
from the data-generating set and observed data are from the test set
Strategy Predicted Observed
HCG LD PLAP TPR FPR LR TPR FPR LR
>6 or >400 & >60 46 0.6 77 54 1.9 28
>6 or >300 & >30 52 0.9 58 60 2.3 26
>6 or >300 or - 55 3.5 16 65 7.5 9
>6 or >400 or - 54 3 18 62 5 12
>6 or >400 or >60 61 3 20 68 6 11
>6 or >300 or >30 66 1 1 6 70 15 5
>3 or >225 or - 58 6 10 64 10 6
TPR - % true positive; FPR - % false positive; LR - likelihood ratio.
>6 IU 1-' or LD > 300 U1-' or PLAP > 30 U 1' is more
sensitive, with the ability to detect 60 to 70% of patients with
disease, the FPR is high between 10 and 15%. Analysis of
patients known to be non-smokers showed that the PLAP
threshold could be lowered to > 35 U 11 without
significantly affecting FPR. Interestingly, there was little
effect on TPR either and so both likelihood ratios and
positive predictive values remained constant (data not
shown).
The positive predictive values, or post-test probabilities,
for the various strategies are shown in Table III. Even
strategies which perform well when the probability of disease
is high perform poorly when this probability is low even
for the best strategy the post test probability is less than
50%, the probabilistic equivalent of a coin toss, when the
pre-test probability of disease is <5%. The comparative
performance of the various strategies in terms of positive
predictive value is illustrated, both for staging and follow-up
in Figure 5. The best predictive values are obtained with the
or/and strategies.
Discussion
In contrast to the non-seminomatous germ cell tumours,
where the tumour markers alpha-foetoprotein and PHCG
have contributed considerably to management (Bosl et al.,
1983), no reliable markers exist for seminoma. At one time
PLAP looked promising (Epenetos et al., 1985) but this
initial promise has not been fulfilled (Nielsen et al., 1990).
The question then arises: might the combination of PLAP,
LD, and PHCG prove more useful in the assessment of
seminoma than simple consideration of individual markers?
The use of multiple tumour markers in combination is
complex (Makuch & Muenz, 1987). The aim is to try to
produce a whole that is in some way greater than the sum of
its parts. If, however, the components are inferior then no
amount of legerdemain will compensate for lack of intrinsic
worth. A variety of mathematical approaches have been ap-
plied to the problem of how best to utilise multiple tumour
markers (Gail et al., 1986; Gail et al., 1988; Lahousen et al.,
1987). These have usually relied upon multivariate techniques
such as logistic regression or linear discriminant analysis.
Recursive partitioning has also proved useful. These tech-
niques are complicated and the multivariate methods require
that assumptions are made regarding the shape of the dis-
tributions of the variables. The techniques are difficult to
appreciate intuitively, seeming to the uninitiated consumer to
be black boxes into which data are fed and whose conclusions
have simply to be taken on trust. We wished to use an
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Figure 5 Positive predictive value (PPV) plotted for staging
(disease prevalence = 30%) against PPV for follow-up (disease
prevalence = 1%). Data are from data generating set:
1. P3HCG >61U1-' or LD >400UI-I and PLAP >60U1l-
2. PHCG >6IU1 or LD >300U1-' and PLAP >30U1-'
3. PHCG >61U1-' or LD >40OU1-'
4. PHCG >61U1-' or LD >400U1' or PLAP >60U1-'
5. 13HCG >61U1-' or LD >300U1-'
6. PHCG >61U1-' or LD >300U1' or PLAP > U1'
Table III The likelihood ratios and positive predictive values for six strategies
Strategy PPVpredicted PPV observed
PHCG LD PLAP LR STG FUP1% FUP5% LR STG FUPI% FUP5%
>6 or >400 & >60 77 97% 44% 80% 28 93% 23% 60%
>6 or >300 & >30 58 96% 34% 73% 26 92% 21% 58%
>6 or >300 or - 16 87% 14% 46% 9 79% 8% 32%
>6 or >400 or - 18 89% 15% 49% 12 84% 11% 39%
>6 or >400 or >30 20 90% 17% 51% 12 84% 11% 39%
>6 or >300 or >30 6 72% 6% 24% 11 68% 5% 21%
STG - staging, pre-test probability ofdisease 30%; FUPI% - follow-up, pre-test probability of
disease 1%; FUPS% - follow-up, pre-test probability of disease 5%.
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approach in which the investigator could deal directly with
the data and from which simple, easily applied, rules might
emerge.
The analytical technique we have used in this study is
conceptually simple. The data drive the analysis directly and
no assumptions concerning the distribution of variables are
required. The resulting strategies are simple and can be
evaluated heuristically using the Markov process and then
validated using the test set. By splitting the patients into a
data generating set and a test set the problem of recur-
siveness is avoided: the strategies are not ultimately applied
to the data from which they have been derived. The Markov
process provides a rapid and convenient method for assaying
strategies. The main disadvantage of the Markov process is
that it treats markers as if they functioned independently and
will overestimate the performance of combined strategies.
Compare the predictions of the Markov analyses in Figure 4
with actual performance shown in Table II. This arises
because the Markov model takes no heed of the fact that
some patients will have, for example, both HCG and LD
elevated. Such interactions cannot readily be incorporated
into a simple model. Hence the need, once the best strategies
have been selected using the Markov model, to go back to
the real data and apply the strategies. If the P HCG is
abnormal then the PLAP and LD are ignored and the sam-
ples with abnormal P HCG levels are censored when PLAP
and LD are considered. The rules which emerge from such
an assessment are simple, and in contrast to those derived
from multivariate techniques, do not involve transformation
of the data or differentially weighted exponentials.
The strategy which performed best was to consider the
following combination of results abnormal: P HCG >6-
IUI- or LD >400UV1' and PLAP >60U1-V. This im-
plies that PLAP need only be measured if the PHCG is
normal, but the LD is >400 U 1'. The addition of the
PLAP result under these circumstances will increase the
likelihood ratio by a factor of approximately 2.5. This
strategy will identify about 50% of patients with disease and
the false positive rate is less than 2%. Although a more
liberal PLAP threshold could be used in patients known to
be non-smokers this did not improve test performance; the
detection rate for active disease was still only 50%.
The usefulness of any strategy will depend upon the
clinical circumstances under which it is applied and will be
profoundly affected by the prior probability, or prevalence,
of disease. For patients with seminoma the main circum-
stances of interest are initial staging and follow-up. The
positive predictive value for a given test or strategy usefully
summarises performance under varying conditions as illus-
trated in Figure 5. However factors, other than statistical,
have also to be considered. At initial staging a relatively high
false positive rate can be tolerated since patients will, in any
event, be having other tests, CT scanning in particular, which
aid in the confirmation or refutation of the presence of
disease. Follow-up is different. The majority of patients are
well, extensive investigations are not routinely performed,
and the false positive rate must therefore be kept low. The
cost, upset, and anxiety engendered by the unnecessary recall
and investigation of patients who are in fact well must be
minimised. Between 60 and 70% of patients with disease will
be detected by a strategy of defining as abnormal P HCG
>6 IU 1' or LD >400 U I1 or PLAP >60 U 1-'. This will
yield a false positive rate of around 5%. This is acceptable
for initial staging but not for follow-up since the probability
of disease in a patient on follow-up defined, by these criteria,
as having an abnormal test result is only 17%.
Previous studies on markers for seminoma have empha-
sised the positive aspect ofpotential markers, ability to detect
disease, and have understated or ignored the negative aspect,
false positivity. For example Fossa & Fossa (1989) have
pointed out that around 70% of relapses would be detected
by accepting as abnormal any sample in which either the
,B HCG or the LD were above the upper limit of normal as
defined by the laboratory. Our own data show, Table II, that
this approach will detect 60% of patients with active disease
but that the false positive rate may be as high as 10%.
There are two main aspects to the use of tumour markers
in clinical oncology - the strategic and the tactical. Both
aspects are dealt with in the current analysis. The strategic
aspect is concerned with the design of policies and rules: how
often should marker estimations be performed, what is an
acceptable compromise between detection rate for active
disease and the rate of false positive results? The tactical
aspect concerns the interpretation of a given marker result in
a given patient at a given time: what is the probability, given
these results, that this patient does, or does not, have disease.
Strategy is assessed in Table II, tactics are covered in Table
III and Figure 5.
Our analysis has concentrated on both the advantages and
disadvantages of various strategies for using tumour markers
in seminoma. By so doing we have reached conclusions that
are both balanced and practical. PLAP is of little use in
routine follow-up and should only be performed when the
P HCG is normal and the LD is >400 U 1'. The best
strategy for the use of markers in initial clinical staging is to
some extent a matter of choice. The best strategy for follow-
up (abnormal if PHCG >61UI-' or LD >400Ul-' and
PLAP >60 U 1') performs acceptably when applied to stag-
ing: it will detect 50% of patients with disease and the
positive predictive value of an abnormal test is well above
90%. The 50% detection rate can be improved, to about
70%, by defining a result as abnormal if P HCG >6 IU I1'
or LD >300 U 1' or PLAP >30 U 1' but the false positive
rate is considerably higher and the positive predictive value
of an abnormal result falls to around 70%.
PLAP need not, therefore, be routinely measured in pa-
tients with seminoma, either at initial clinical staging or at
follow-up. P HCG and LD should be assessed routinely at all
visits. When doubt about the presence or absence of disease
exists, arising either from elevated LD with a normal P HCG,
or from clinical or radiological findings, then estimation of
PLAP may prove helpful in removing the uncertainty.
We would like to thank Brigitte Caplan for technical help and
Deborah Tsuji for help with data collection.
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